Kymera rises after presentation at the J.P. Morgan event
Kymera Therapeutics (KYMR) stock surged as the company outlined its 2025 outlook at the J.P. Morgan Healthcare Conference. Read more here.
Kymera stock surges on product pipeline update
On Tuesday, Kymera Therapeutics shares leaped 12% following the biotechnology firm's update on its product pipeline. The New York-based company announced progress in its programs for atopic dermatitis ...
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...